论文部分内容阅读
目的:观察补肾益肺方联合西药治疗慢性阻塞性肺疾病缓解期患者的临床疗效。方法:将68例慢性阻塞性肺疾病缓解期患者随机分为观察组36例和对照组32例。观察组采用中药汤剂补肾益肺方联合西药治疗,对照组采用西药治疗。2组疗程均为1月。对比分析2组的疗效、肺功能指标、血气分析指标、生存质量积分及不良反应发生情况。结果:观察组总有效率(94.44%)高于对照组(68.75%)(P<0.05)。治疗后,2组用力肺活量(FVC)、最大通气量(MVV)均较治疗前上升(P<0.05),而第1秒用力呼气容积(FEV1)较治疗前无改善(P>0.05);观察组FVC、MVV均高于对照组(P<0.05)。观察组动脉血氧分压(PaO_2)高于对照组(P<0.05),二氧化碳分压(PaCO_2)、生存质量积分均低于对照组(P<0.05)。治疗期间2组均未见明显不良反应。结论:补肾益肺方联合西药治疗慢性阻塞性肺疾病缓解期临床疗效显著,能够明显改善患者的肺功能、提高患者的生存质量,具有重要临床研究意义。
Objective: To observe the clinical efficacy of Bushen Yifei Recipe combined with western medicine in the treatment of patients with chronic obstructive pulmonary disease (COPD) at remission stage. Methods: Sixty-eight patients with chronic obstructive pulmonary disease (COPD) were randomly divided into observation group (36 cases) and control group (32 cases). The observation group was treated with traditional Chinese medicine Decoction Bushen Yixiang Fang in combination with western medicine, while the control group was treated with western medicine. 2 groups of treatment are January. The curative effect, pulmonary function index, blood gas analysis index, quality of life integral and adverse reactions of two groups were compared and analyzed. Results: The total effective rate (94.44%) in the observation group was higher than that in the control group (68.75%) (P <0.05). After treatment, the forced vital capacity (FVC) and maximal ventilation (MVV) in two groups were significantly higher than those before treatment (P <0.05), while FEV1 was not improved before treatment (P> 0.05). The FVC and MVV in the observation group were higher than those in the control group (P <0.05). The PaO2 in the observation group was higher than that in the control group (P <0.05), while the PaCO2 and quality of life points were lower in the observation group than those in the control group (P <0.05). There was no obvious adverse reaction in the two groups during the treatment. Conclusion: Bushen Yifei Recipe combined with western medicine has significant clinical effect in remission stage of chronic obstructive pulmonary disease, which can significantly improve lung function and improve quality of life of patients with clinical significance.